Latest news

CardiNor signs US distribution agreement with IBL-America for the CardiNor Research Use Only Secretoneurin ELISA test.

Press releases

2022

CardiNor signs US distribution agreement with IBL-America for the CardiNor Research Use Only Secretoneurin ELISA test

CardiNor announces CE marking and launch of new Cardiovascular risk marker: The CardiNor Secretoneurin ELISA test

2021

CardiNor secures NOK12 million to commercialise first secretoneurin (SN) ELISA test

2018

CardiNor AS Eurostars funding, March 2018

2016

New Data Supports Correlation Between Secretoneurin and Cardiovascular Disease

Bioventix invests in CVD diagnostics start-up CardiNor Companies to jointly develop “missing link” Secretoneurin biomarker

2015

CardiNor receives USD 0.75M to develop “missing link” CV risk test.

In the media

Unicard, 17.11.2016: (secretoneurin predicts mortality in patients with acute respiratory failure. Article in Norwegian)

Secretoneurin forutsier død ved akutt respirasjonssvikt

Scientific Nordic, 02.10.2015:

Peptide found that predicts heart failure

Unicard, 12.03.2015:

Blodprøve kan fange opp risikopasienter ved hjertesvikt

VG, 27.09.2015:

Dette stoffet kan forutsi hjertedød.

Events

Poster accepted for presentation at European Society of Cardiology annual meeting in Munich on 28th of august. Low concentrations of circulating secretoneurin predict a favourable prognosis after cardiac surgery

Presentations

Developing the “missing link” biomarker test for cardiovascular disease

Contact Us

Send us an email and we'll get back to you, asap.